Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group
Doreen G. Te Raa(Ziekenhuis Gelderse Vallei), Lina van der Straten(Erasmus MC), Jeanette K. Doorduijn(Université Paris Cité), Michel van Gelder(Maastricht University), Eduardus F. M. Posthuma(Leiden University Medical Center), Rogier Mous(University Medical Center Utrecht), Sabina Kersting(Haga Hospital), Mar Bellido(University Medical Center Groningen), Ellen van der Spek(Rijnstate Hospital), Marjolein van der Klift(Amphia Ziekenhuis), Anke H. W. Bruns(Utrecht University), Koen de Heer, Arnon P. Kater(Sanford Burnham Prebys Medical Discovery Institute), Hanneke M. Straaten(Rijnstate Hospital), Hein P. J. Visser(Northwest Hospital), Marten R. Nijziel(Radboud University Nijmegen), Mark‐David Levin(Albert Schweitzer Ziekenhuis), Reinier A. P. Raijmakers(Utrecht University)
Cited by 4
Related Papers
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
|The Lancet|2021|337
Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network
|Journal of Clinical Oncology|2014|164